HIPRA

Company Premium

HIPRA is a multinational pharmaceutical company focused on prevention and diagnosis for animal and human health, with a broad range of highly innovative vaccines and an advanced diagnostic service. With its claim “Building immunity for a healthier world”, HIPRA affirms its commitment to contributing with solutions that improve world health.

HIPRA has a solid international presence in more than 39 countries, with its own subsidiaries, 11 diagnostic centres and 2 production plants strategically located in Europe (Spain) and America (Brazil).

Moreover, its extensive international distribution network keeps open marketing channels with nearly 100 other countries, thereby covering the 5 continents.

Research and Development constitute the core of its knowledge. HIPRA dedicates 10% of its annual turnover to R&D activities that concentrate on the creation and application of the latest scientific advances to the development of the highest quality innovative vaccines. To give added value to its vaccination experience, the company also develops medical devices and traceability services.

HIPRA performs and monitors all the production stages of its services and biological products in its facilities, which are equipped with the latest technological advances. HIPRA is the company that has launched the most biotech vaccines in the last 10 years, with a total of 22 vaccines.

HIPRA is ranked as one of the global leaders in the veterinary industry developing vaccines for Animal Health.

See more

Danish national PRRS reduction strategy - Status year 1

By May 2023, 85% of all Danish pig herds have a serological PRRS status. Area eradication programs have been established in regions with a high density of PRRS seropositive herds. The Danish Agriculture & Food Council has taken a range of initiatives with the purpose of paving the road for a national reduction of PRRS, including an implementation strategy, digital tools, common guidelines for the classification, monitoring, and eradication of PRRSV, and project funding resources.

PRRS hot topics

We summarize our discussion with Dr. Hans Nauwynck, professor at Ghent University, related to several PRRS hot topics: autovaccines, regional control and elimination, boar studs, and replacement gilts PRRS status.

Welcome to 333

Connect, share, and interact with the largest community of professionals in the swine industry.

Celebrating 136931Users on 333!

Sign upAlready a member?
Recommended accounts
Wang  Lily

Wang Lily

Other - China
Zhou  Lydia

Zhou Lydia

Other - China
Boehringer Ingelheim Vetmedica GmbH
Company - Germany
Tonisity

Tonisity

Company - Ireland
Crystal Spring Hog Equipment
Company - Canada